北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第五次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 EUME 3 PT VIJAN LAW OFFICES 北京 BEIJING ·上海 SHANGHAI ·深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:深圳华大智造科技股份有限公司 北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第五次临时股东大会的 法律意见书 嘉源(2025)-04-867 北京市嘉源律师事务所(以下简称"本所")接受深圳华大智造科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《深圳华大智造科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司2025年第五次临时股东大会(以下简称"本次股 东大会"）进行见证,并依法出具本法律意见书。 为 ...

深圳华大智造科技股份有限公司 证券代码：688114 证券简称：华大智造 公告编号：2025-074 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 26 日 （二） 股东大会召开的地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议中心 419 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 127 | | --- | --- | | 普通股股东人数 | 127 | | 2、出席会议的股东所持有的表决权数量 | 222,169,043 | | 普通股股东所持有表决权数量 | 222,169,043 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 53.8554 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

11 月 21 日，以 " 智领健康未来 " 为主题的 2025 华夏大健康产业发展暨康复服务大会在北京召开。作为连续四届引领行业风向的标杆盛会，科技与创新 始终是贯穿全程的灵魂主线，而医疗健康企业在环境、社会及治理方面的表现同样被社会各界关注。 万得 ESG高级分析师 受邀发表了主题演讲，详细介绍了蒲公英指数的构建背景、评估体系及市场表现，强调该指数为医疗健康行业可持续发展提供了重 要参考。 万得首先介绍了 Wind 万得的业务背景： "Wind 是一家专业化的信息服务机构，为金融领域开发了信息检索、数据提取及组合管理等专业工具，是国内外 机构投资者的重要合作伙伴。 " 她特别指出， Wind 构建的独立 ESG 评级体系已广泛应用于政策研究、金融决策和企业实践当中，例如国务院发展研究 中心发布的报告及可持续挂钩债券发行实践。 蒲公英指数亦是 Wind ESG 评级体系的一次创新性应用。该指数由华夏时报大健康研究院与万得联合研发，从医疗健康领域 A 股 495 家公司中精选前 50 家组成 " 蒲公英 50 指数 " ，港股 262 家公司中精选 30 家组成 " 蒲公英 30 指数 " ，每月根据 ESG ...

Market Overview - The precision medicine sector experienced a decline of 1.61% on November 21, with Berry Genomics leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the precision medicine sector showed varied performance, with the following notable changes: - United Imaging Healthcare (688271) increased by 2.15% to a closing price of 133.50 [1] - Berry Genomics (000710) fell by 8.67% to a closing price of 11.59, with a trading volume of 233,200 shares and a turnover of 278 million [2] - WuXi AppTec (603259) decreased by 2.00% to a closing price of 91.80, with a significant trading volume of 346,800 shares and a turnover of 3.197 billion [1] Capital Flow - The precision medicine sector saw a net outflow of 678 million from institutional investors, while retail investors contributed a net inflow of 705 million [2] - The following stocks experienced notable capital flows: - New Open Source (300109) had a net inflow of 22.76 million from institutional investors [3] - ST Xiangxue (300147) faced a significant net outflow of 17.12 million from institutional investors [3]

| 年第五次临时股东大会会议须知 3 2025 | | --- | | 2025 年第五次临时股东大会会议议程 5 | | 年第五次临时股东大会会议议案 7 2025 | | 《关于修订〈公司章程〉并办理工商变更登记的议案》 7 | | 《关于修订、制定公司部分治理制度的议案》 8 | | 《关于增加公司 2025 年度日常关联交易预计额度的议案》 10 | | 《关于使用部分超募资金永久补充流动资金的议案》 12 | 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会 会议资料 2025 年 11 月 1 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议须知 为保障深圳华大智造科技股份有限公司（以下简称"公司"）全体股东的合 法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大 会如期、顺利召开，根据《中华人民共和国公司法》（以下简称《公司法》）、 《深圳华大智造科技股份有限公司章程》（以下简称《公司章程》）、《深圳华 大智造 ...

Core Points - Shenzhen BGI Genomics Co., Ltd. announced a change in its continuous supervision sponsor representative [1] - CITIC Securities, the sponsor for the company's 2022 A-share IPO project, has replaced the original representative due to work adjustments [1] - The new sponsor representatives are Lu Ming and Wang Helin, ensuring the continuity of supervision duties [1] Summary by Sections - **Company Announcement** - The company confirms the authenticity and completeness of the announcement [2] - The board expresses gratitude to the outgoing representative for his contributions [1] - **Change of Sponsor Representative** - The original sponsor representative, Xiao Shaochun, is replaced by Wang Helin to maintain orderly supervision [1] - The continuous supervision period is set to last until December 31, 2025 [1]

Core Viewpoint - BGI Genomics announced a change in its sponsor representative for the ongoing supervision of its 2022 A-share IPO project, ensuring continuity in oversight responsibilities [1] Group 1 - CITIC Securities was appointed as the sponsor for BGI Genomics' 2022 A-share IPO project, with the supervision period lasting until December 31, 2025 [1] - The original sponsor representatives, Mr. Xiao Shaochun and Mr. Lu Ming, were responsible for the continuous supervision duties [1] - Mr. Xiao Shaochun will no longer be responsible for the supervision due to a work adjustment, and Mr. Wang Helin has been appointed to take over his responsibilities [1]

深圳华大智造科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于近日收到中信证券 股份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》。 中信证券作为公司 2022 年 A 股首次公开发行项目的保荐机构，原委派肖少春先 生和路明先生为保荐代表人履行持续督导职责，持续督导期至 2025 年 12 月 31 日止。 证券代码：688114 证券简称：华大智造 公告编号：2025-073 原保荐代表人肖少春先生现因工作调整，不再负责对公司的持续督导工作， 为保证持续督导工作的有序进行，中信证券现委派王贺麟先生（简历详见附件） 接替肖少春先生担任公司的保荐代表人，并继续履行持续督导的相关职责和义务。 本次变更后，公司 2022 年 A 股首次公开发行项目的保荐代表人为路明先生 和王贺麟先生。本次变更不影响中信证券对公司的持续督导工作，公司董事会对 肖少春先生在担任公司保荐代表人期间做出的贡献表示衷心感谢！ 特此公告。 王贺 ...

Core Viewpoint - The company reported its Q3 2025 earnings, achieving revenue of 1.869 billion yuan, which is essentially flat year-on-year, and a net profit attributable to shareholders of -120 million yuan, an improvement from -463 million yuan in the same period last year, indicating a reduction in losses and meeting prior expectations [1][2][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.869 billion yuan, with a net profit attributable to shareholders of -120 million yuan, compared to -463 million yuan in the previous year, and a non-recurring net profit of -228 million yuan, improving from -497 million yuan year-on-year [3][4]. - In Q3 2025, the company reported revenue of 755 million yuan, a year-on-year increase of 14.45%, driven by steady progress in domestic substitution and accelerated development in automation and multi-omics businesses [3][4]. - The company’s gross margin for the first three quarters was 53.32%, down 8.15 percentage points, primarily due to competitive pressures affecting product margins [8]. Business Segments - The full-read long sequencing business saw a steady increase in instrument sales, with the successful launch of the T7+ product, although instrument sales revenue slightly declined due to product mix effects [4]. - The smart automation business segment has been upgraded to focus on automation, with steady revenue growth in the first three quarters of 2025 [5]. Technological Advancements - The company is actively applying AI technologies in its smart automation business, enhancing its capabilities through new platforms and modules, which are expected to improve efficiency and reduce costs [5]. - A licensing agreement with SwissRockets for the CoolMPS sequencing technology is expected to generate at least 120 million USD in upfront payments and milestone payments, reflecting the company's technological leadership [6][7]. Future Outlook - The company is well-positioned to benefit from the domestic substitution trend, especially following the U.S. restrictions on Illumina, which may enhance its market share [9]. - The global sequencing industry is expected to see improved demand as macroeconomic conditions stabilize, with the company’s losses anticipated to narrow as operational efficiencies improve [9][10]. - Revenue projections for 2025-2027 are 3.041 billion, 3.389 billion, and 3.763 billion yuan, with net profits expected to improve significantly over the same period [10].